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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 37th prioritisation (October 2018), 14 drugs were filtered out of 477 identified and were sent 
to prioritisation. Of these, 6 drugs were ranked as ‘highly relevant’ by the expert panel, 7 as 
‘relevant’ and 1 as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
No Filtered Drugs – 37th prioritisation 4th quarter 2018 Overall 
category 
1. 
Apalutamide (Erleada®) treatment and metastasis-free survival in 
prostate cancer 
Highly relevant 
2. 
Enzalutamide (Xtandi®, MDV3100) in men with nonmetastatic, castration-
resistant prostate cancer 
Highly relevant 
3. 
Blinatumomab (Blincyto®) for minimal residual disease (MRD) in adults 
with B-cell precursor acute lymphoblastic leukaemia (ALL) 
Highly relevant 
4. 
Adjuvant pembrolizumab (Keytruda®) versus placebo in resected stage III 
melanoma 
Highly relevant 
5. 
Adjuvant bevacizumab (Avastin®) for melanoma patients at high risk of 
recurrence 
Not relevant 
6. 
Combined nivolumab (Opdivo®, BMS-936558, MDX1106, ONO4538 ) 
and ipilimumab in melanoma metastatic to the brain 
Relevant 
7. 
Atezolizumab (Tecentriq®) for first-line treatment of metastatic 
nonsquamous non-small-cell lung cancer (NSCLC) 
Relevant 
8. 
Cabozantinib (Cometriq®, Cabometyx®) in patients with advanced and 
progressing hepatocellular carcinoma (HCC) 
Relevant 
9. 
Pembrolizumab (Keytruda®) in patients with advanced hepatocellular 
carcinoma (HCC) previously treated with sorafenib 
Relevant 
10. Ibrutinib (Imbruvica®) plus rituximab in Waldenstrom’s macroglobulinemia Highly relevant 
11. 
Mogamulizumab (Poteligeo®, KW-0761) versus vorinostat in previously 
treated cutaneous T-cell lymphoma 
Relevant 
12. 
Ribociclib (Kisqali®) and fulvestrant in hormone receptor–positive, human 
epidermal growth factor receptor 2–negative advanced breast cancer 
Relevant 
13. 
Ribociclib (Kisqali®) plus endocrine therapy for premenopausal women 
with hormone-receptor-positive, advanced breast cancer 
Highly relevant 
14. 
Talazoparib (BMN 673) in patients with advanced breast cancer and a 
germline BRCA mutation 
Relevant 
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1 Prostate Cancer 
1.1 Apalutamide (Erleada®) treatment and metastasis-free survival 
in prostate cancer 
Overview 
Drug Description a competitive inhibitor of the androgen receptor 
Patient Indication 
patients with nonmetastatic castration-resistant prostate cancer who are at 
high risk for the development of metastasis 
Incidence in 
Austria 
4,854 newly diagnosed per year (2015), 130.6/100,000 men/year 
(European Standard Population, 2013) 
Ongoing Phase III 
 
NCT01946204 (SPARTAN) ongoing until 08/2019 
NCT02489318 until 07/2022 
NCT02257736 until 08/2021 
 
Approval 
status for 
this 
indication 
EMA - 
FDA 
02/2018: the FDA approved apalutamide for patients with non-metastatic 
castration-resistant prostate cancer  
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs - 
Published articles (PubMed): 
NEJM; available online February 8, 2018 (Smith et al.): “Apalutamide treatment and metastasis-free 
survival in prostate cancer”   
  
Background 
Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment 
of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-
resistant prostate cancer who were at high risk for the development of metastasis. 
Methods 
We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic 
castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. 
Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. 
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All the patients continued to receive androgen-deprivation therapy. The primary end point was 
metastasis-free survival, which was defined as the time from randomization to the first detection of 
distant metastasis on imaging or death. 
Results 
A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo 
group). In the planned primary analysis, which was performed after 378 events had occurred, median 
metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in 
the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 
0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with 
placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to 
discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo 
group. The following adverse events occurred at a higher rate with apalutamide than with placebo: 
rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%). 
Interpretation 
Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time 
to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by 
Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204.) 
1.2 Enzalutamide (Xtandi®, MDV3100) in men with nonmetastatic, 
castration-resistant prostate cancer 
Overview 
Drug Description 
enzalutamide binds directly to the androgen receptor and inhibits the 
binding of androgens, androgen-receptor nuclear translocation, and 
androgen-receptor–mediated DNA binding 
Patient Indication patients with nonmetastatic, castration-resistant prostate cancer 
Incidence in 
Austria 
4,854 newly diagnosed per year (2015), 130.6/100,000 men/year 
(European Standard Population, 2013) 
Ongoing Phase III 
NCT02003924 (PROSPER) until 05/2020 
NCT02987543 until 02/2021 
NCT02288247 until 12/2019 
NCT03016312 until 07/2022 
NCT03395197 until 03/2024 
NCT01949337 until 12/2019 
Approval 
status for 
this 
indication 
EMA - 
FDA 
 
according to label information (07/2018) enzalutamide is indicated for the 
treatment of patients with castration-resistant prostate cancer 
 
Approval 
status for 
other 
indications 
EMA 
according to product information (updated 04/2018), enzalutamide is 
indicated for  
- the treatment of adult men with metastatic castration-resistant 
prostate cancer who are asymptomatic or mildly symptomatic after 
failure of androgen deprivation therapy in whom chemotherapy is 
not yet clinically indicated  
- the treatment of adult men with metastatic castration-resistant 
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prostate cancer whose disease has progressed on or after 
docetaxel therapy 
FDA - 
Costs  
 
112 Xtandi® soft capsules (40mg) = € 2,895.35 (ex-factory price) 
 
PROSPER study patients received enzalutamide at a dose of 160 mg 
once daily, the median duration of treatment was 18.4 months.  
 
Based on study treatment, 28 days of enzalutamide treatment would cost 
€ 2,895.35; 18.4 months of treatment would cost € 53,274.44. 
 
 
Published articles (PubMed): 
NEJM 2018; 378:2465-74 (Hussain et al.): “Enzalutamide in men with nonmetastatic, castration-
resistant prostate cancer” 
Background  
Men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising prostate-specific 
antigen (PSA) level are at high risk for metastasis. We hypothesized that enzalutamide, which 
prolongs overall survival among patients with metastatic, castration-resistant prostate cancer, would 
delay metastasis in men with nonmetastatic, castration-resistant prostate cancer and a rapidly rising 
PSA level. 
 
Methods  
In this double-blind, phase 3 trial, we randomly assigned, in a 2:1 ratio, men with nonmetastatic, 
castration-resistant prostate cancer and a PSA doubling time of 10 months or less who were 
continuing androgen-deprivation therapy to receive enzalutamide (at a dose of 160 mg) or placebo 
once daily. The primary end point was metastasis-free survival (defined as the time from 
randomization to radiographic progression or as the time to death without radiographic progression). 
 
Findings  
A total of 1401 patients (median PSA doubling time, 3.7 months) underwent randomization. As of June 
28, 2017, a total of 219 of 933 patients (23%) in the enzalutamide group had metastasis or had died, 
as compared with 228 of 468 (49%) in the placebo group. The median metastasis-free survival was 
36.6 months in the enzalutamide group versus 14.7 months in the placebo group (hazard ratio for 
metastasis or death, 0.29; 95% confidence interval, 0.24 to 0.35; P<0.001). The time to the first use of 
a subsequent antineoplastic therapy was longer with enzalutamide treatment than with placebo (39.6 
vs. 17.7 months; hazard ratio, 0.21; P<0.001; such therapy was used in 15% vs. 48% of patients) as 
was the time to PSA progression (37.2 vs. 3.9 months; hazard ratio, 0.07; P<0.001; progression 
occurred in 22% vs. 69% of patients). At the first interim analysis of overall survival, 103 patients 
(11%) receiving enzalutamide and 62 (13%) receiving placebo had died. Adverse events of grade 3 or 
higher occurred in 31% of the patients receiving enzalutamide, as compared with 23% of those 
receiving placebo. 
 
Interpretation  
Among men with nonmetastatic, castration-resistant prostate cancer with a rapidly rising PSA level, 
enzalutamide treatment led to a clinically meaningful and significant 71% lower risk of metastasis or 
death than placebo. Adverse events were consistent with the established safety profile of 
enzalutamide. (Funded by Pfizer and Astellas Pharma; PROSPER ClinicalTrials.gov number, 
NCT02003924.) 
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2 Leukaemia 
2.1 Blinatumomab (Blincyto®) for minimal residual disease (MRD) 
in adults with B-cell precursor acute lymphoblastic leukaemia 
(ALL) 
Overview 
Drug Description 
 
a bispecific T cell–engager antibody construct that directs T cells to CD19+ 
cells 
Patient Indication 
 
patients with B-cell precursor ALL in first or later haematologic complete 
remission (CR) and with persistent or recurrent MRD ≥ 10-3 after a 
minimum of 3 blocks of intensive chemotherapy 
 
Incidence in 
Austria 
 
ALL total incidence rate: 1.1/100,000/year  
 
Ongoing Phase III 
 
NCT01207388 (BLAST) ongoing until 01/2019 
NCT03476239 until 11/2021 
NCT02101853 until 03/2022 
NCT02393859 until 12/2022 
 
Approval 
status for 
this 
indication 
EMA 
 
07/2009: orphan designation was granted for blinatumomab for the 
treatment of ALL 
 
11/2015: approved for the treatment of adults with Philadelphia 
chromosome negative relapsed or refractory B-precursor ALL 
 
FDA 
 
12/2014: indicated for treatment of Philadelphia chromosomenegative 
relapsed or refractory B-cell precursor ALL 
 
03/2018: indicated for the treatment of adults and children with B-cell 
precursor ALL in first or second CR with MRD greater than or equal to 
0.1% (accelerated approval)  
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs  
 
Blincyto® 38.5 micrograms powder for concentrate and solution for 
infusion, one vial = € 2826.08 (ex-factory price). 
 
BLAST-trial: patients received 15 μg/m2/day (IV) of blinatumomab for 4 
weeks, followed by 2 treatment-free weeks (=1 cycle). 1 dose = 25.95 
μg/day. Costs for one cycle = € 84,782.4.  
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Published articles (PubMed): 
Blood Journal (2018); 131(14):1522-1531 Gökbuget N et al.: “Blinatumomab for minimal residual 
disease in adults with B-cell precursor acute lymphoblastic leukemia” 
 
Background  
Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete 
remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase–
polymerase chain reaction or flow cytometry. MRD is the strongest predictor of relapse in ALL. 
 
Methods  
In this open-label, single-arm study, adults with B-cell precursor ALL in hematologic complete 
remission with MRD (≥ 10-3) received blinatumomab 15 μg/m2 per day by continuous IV infusion for up 
to 4 cycles. Patients could undergo allogeneic hematopoietic stem-cell transplantation any time after 
cycle 1. The primary end point was complete MRD response status after 1 cycle of blinatumomab. 
 
Findings  
One hundred sixteen patients received blinatumomab. Eighty-eight (78%) of 113 evaluable patients 
achieved a complete MRD response. In the subgroup of 110 patients with Ph-negative ALL in 
hematologic remission, the Kaplan- Meier estimate of relapse-free survival (RFS) at 18 months was 
54%. Median overall survival (OS) was 36.5 months. In landmark analyses, complete MRD 
responders had longer RFS (23.6 vs. 5.7 months; P = .002) and OS (38.9 vs. 12.5 months; P = .002) 
compared with MRD nonresponders. Adverse events were consistent with previous studies of 
blinatumomab. Twelve (10%) and 3 patients (3%) had grade 3 or 4 neurologic events, respectively. 
Four patients (3%) had cytokine release syndrome grade 1, n 5 2; grade 3, n 5 2), all during cycle 1. 
 
Interpretation  
After treatment with blinatumomab in a population of patients with MRD-positive B-cell precursor ALL, 
a majority achieved a complete MRD response, which was associated with significantly longer RFS 
and OS compared with MRD nonresponders. This study is registered at www.clinicaltrials.gov as 
#NCT01207388. (Blood. 2018; 131(14):1522-1531). 
 
  
Ergänzende Informationen zu den Arzneistoffen für Priorisierung XXXVII – HSS Onkologie Seite 9 von 15 
3 Melanoma 
3.1 Adjuvant pembrolizumab (Keytruda®) versus placebo in 
resected stage III melanoma 
Overview 
Drug Description a programmed death 1 (PD-1) inhibitor 
Patient Indication 
 
patients with cutaneous melanoma with metastasis to regional lymph 
nodes; the patients had to have either stage IIIA melanoma (patients with 
stage N1a melanoma had to have at least one micrometastasis measuring 
>1 mm in greatest diameter) or stage IIIB or IIIC disease with no in-transit 
metastases  
 
Incidence in 
Austria 
 
1,779 newly diagnosed per year (2015), 20.7/100,000 persons/year 
(European Standard Population, 2013) 
 
Ongoing Phase III 
 
NCT02362594 (Keynote-054) ongoing until 07/2025 
NCT02506153 until 09/2023 
 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
 
according to product information (updated 04/2018), pembrolizumab is 
indicated: 
- as monotherapy for the treatment of advanced (unresectable or 
metastatic) melanoma in adults 
- as monotherapy for the first-line treatment of metastatic non-small 
cell lung carcinoma (NSCLC) in adults whose tumours express 
PD-L1 with a ≥ 50% tumour proportion score (TPS) with no EGFR 
or ALK positive tumour mutations 
- as monotherapy for the treatment of locally advanced or 
metastatic NSCLC in adults whose tumours express PD-L1 with a 
≥ 1% TPS and who have received at least one prior chemotherapy 
regimen; patients with EGFR or ALK positive tumour mutations 
should also have received targeted therapy before receiving 
pembrolizumab 
- as monotherapy for the treatment of adult patients with relapsed or  
refractory classical Hodgkin lymphoma (cHL) who have failed 
autologous stem cell transplant (ASCT) and brentuximab vedotin 
(BV), or who are transplant -ineligible and have failed BV 
- as monotherapy for the treatment of locally advanced or 
metastatic urothelial carcinoma in adults who have received prior 
platinum -containing chemotherapy  
- as monotherapy for the treatment of locally advanced or 
metastatic urothelial carcinoma in adults who are not eligible for 
cisplatin -containing chemotherapy 
FDA 
 
according to label information (11/2017), pembrolizumab is indicated: 
- for  the treatment of patients with unresectable or metastatic 
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melanoma 
- as a single agent for the first-line treatment of patients with 
metastatic NSCLC whose tumors have high PD -L1 expression 
[(Tumor Proportion Score (TPS) ≥50%)] as determined by an 
FDA-approved test, with no EGFR or ALK genomic tumor 
aberrations 
- as a single agent for the treatment of patients with metastatic 
NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined 
by an FDA-approved test, with disease progression on or after 
platinum-containing chemotherapy; patients with EGFR or ALK 
genomic tumor aberrations should have disease progression on  
FDA -approved therapy for these aberrations prior to receiving 
pembrolizumab  
- in combination with pemetrexed and carboplatin, as first-line 
treatment of patients with metastatic nonsquamous NSCLC 
(accelerated approval)  
- for the treatment of patients with recurrent or metastatic head and 
neck squamous cell cancer (HNSCC) with disease progression on 
or after platinum-containing chemotherapy (accelerated approval) 
- for the treatment of adult and pediatric patients with refractory 
classical Hodgkin lymphoma (cHL), or who have relapsed after 3 
or more prior lines of therapy (accelerated approval) 
- for the treatment of patients with locally advanced or metastatic  
urothelial carcinoma who are not eligible for cisplatin-containing 
chemotherapy (accelerated approval) 
- for the treatment of patients with locally advanced or metastatic 
urothelial carcinoma who have disease progression during or 
following platinum-containing chemotherapy or within 12 months 
of neoadjuvant or adjuvant treatment with platinum-containing 
chemotherapy 
- for the treatment of adult and pediatric patients with unresectable 
or metastatic, microsatellite instability-high (MSI-H) or mismatch 
repair deficient solid tumors that have progressed following prior 
treatment and who have no satisfactory alternative treatment 
options, or colorectal cancer that has progressed following 
treatment with a fluoropyrimidine, oxaliplatin, and irinotecan 
(accelerated approval). Limitation of Use: The safety and 
effectiveness of pembrolizumab in pediatric patients with MSI-H 
central nervous system cancers have not been established 
- for the treatment of patients with recurrent locally advanced or 
metastatic gastric or gastroesophageal junction adenocarcinoma 
whose tumors express PD-L1 [Combined Positive Score (CPS) 
≥1] as determined by an FDA-approved test, with disease 
progression on or after two or more prior lines of therapy including 
fluoropyrimidine- and platinum-containing chemotherapy and if 
appropriate, HER2/neu-targeted therapy (accelerated approval). 
 
Costs  
 
Keytruda® 50 mg powder for concentrate for solution for infusion = € 
1,714.00 (ex-factory price).  
Trial patients received either 200 mg (€ 6,856.00/ per dose) of 
pembrolizumab or placebo intravenously every 3 weeks for a total of 18 
doses (€ 123,408.00/18 doses) 
 
Published articles (PubMed): 
NEJM; available online 15 April, 2018 (Eggermont et al.): “Adjuvant pembrolizumab versus placebo 
in resected stage III melanoma” 
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Background  
The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free 
and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind 
trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III 
melanoma. 
 
Methods  
Patients with completely resected stage III melanoma were randomly assigned (with stratification 
according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) 
or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or 
until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall 
intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 
ligand (PD-L1) were the primary end points. Safety was also evaluated. 
 
Findings  
At a median follow-up of 15 months, pembrolizumab was associated with significantly longer 
recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of 
recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 
65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup 
of 853 patients with PD-L1–positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 
72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; 
hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related 
to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of 
patients in the placebo group. There was one treatment-related death due to myositis in the 
pembrolizumab group. 
 
Interpretation  
As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 
weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no 
new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594; EudraCT 
number, 2014-004944-37.) 
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4 Lymphoma 
4.1 Ibrutinib (Imbruvica®) plus rituximab in Waldenstrom’s 
macroglobulinemia 
Overview 
Drug Description a tyrosine kinase inhibitor 
Patient Indication patients with Waldenstrom´s macroglobulinemia who had not received 
previous treatment and patients with disease recurrence 
Incidence in 
Austria 
 
Waldenstrom´s macroglobulinemia accounts for approx. 1-3% of all non-
Hodgkin ´s lymphomas (NHL).  
NHL: 1,318 newly diagnosed per year (2015), 15.5/100,000 persons/year 
(European Standard Population)  
 
Ongoing Phase III 
NCT02165397 until 01/2019 
NCT03053440 until 06/2021 
Approval 
status for 
this 
indication 
EMA - 
FDA according to label information (02/2018) ibrutinib is indicated for the 
treatment of adult patients with Waldenström’s macroglobulinemia 
Approval 
status for 
other 
indications 
EMA 
according to product information (updated 08/2018) ibrutinib is indicated  
- as a single agent for the treatment of adult patients with relapsed 
or refractory mantle cell lymphoma (MCL) 
- as a single agent for the treatment of adult patients with previously 
untreated chronic lymphocytic leukaemia (CLL) 
- as a single agent or in combination with bendamustine and 
rituximabfor the treatment of adult patients with CLL who have 
received at least one prior therapy 
- as a single agent for the treatment of adult patients with 
Waldenström’s macroglobulinaemia who have received at least 
one prior therapy, or in first line treatment for patients unsuitable 
for chemo-immunotherapy 
FDA 
according to label information, ibrutinib is indicated for the treatment of 
adult patients with: 
- mantle cell lymphoma (MCL) who have received at least one prior  
therapy (accelerated approval)  
- chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma  
(SLL)  
- chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma  
(SLL) with 17p deletion  
- marginal zone lymphoma (MZL) who require systemic therapy and 
have received at least one prior anti-CD20-based therapy 
(accelerated approval) 
- chronic graft versus host disease (cGVHD) after failure of one or 
more lines of systemic therapy 
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Costs  
 90  Imbruvica® hard capsules 140 mg = € 5474.70 
120 Imbruvica® hard capsules 140 mg = € 7299.60 
 
Study patients assigned to the ibrutinib-rituximab-group received 420 mg 
of ibrutinib orally once daily; the median duration of treatment among 
patients of this group was 25.8 months. 
 
One month (30 days) of ibrutinib treatment would cost € 5474.70, for 25.8 
months of treatment, costs of € 141,247.26 would incur (plus additional 
costs for rituximab) 
 
Published articles (PubMed): 
NEJM; available online June 1, 2018 (Dimopoulos et al.): “Phase 3 trial of ibrutinib plus rituximab in 
Waldenstrom’s macroglobulinemia” 
 
Background  
Single-agent ibrutinib has shown substantial activity in patients with relapsed Waldenstrom’s 
macroglobulinemia, a rare form of B-cell lymphoma. We evaluated the effect of adding ibrutinib to 
rituximab in patients with this disease, both in those who had not received previous treatment and in 
those with disease recurrence. 
 
Methods  
We randomly assigned 150 symptomatic patients to receive ibrutinib plus rituximab or placebo plus 
rituximab. The primary end point was progression-free survival, as assessed by an independent 
review committee. Key secondary end points were response rates, sustained hematologic 
improvement from baseline, and safety. The mutational status of MYD88 and CXCR4 was assessed in 
bone marrow samples.  
 
Findings  
At 30 months, the progression-free survival rate was 82% with ibrutinib–rituximab versus 28% with 
placebo–rituximab (hazard ratio for progression or death, 0.20; P<0.001). The benefit in the ibrutinib–
rituximab group over that in the placebo–rituximab group was independent of the MYD88 or CXCR4 
genotype. The rate of major response was higher with ibrutinib–rituximab than with placebo–rituximab 
(72% vs. 32%, P<0.001). More patients had sustained increases in hemoglobin level with ibrutinib– 
rituximab than with placebo–rituximab (73% vs. 41%, P<0.001). The most common adverse events of 
any grade with ibrutinib–rituximab included infusion-related reactions, diarrhea, arthralgia, and nausea. 
Events of grade 3 or higher that occurred more frequently with ibrutinib–rituximab than with placebo–
rituximab included atrial fibrillation (12% vs. 1%) and hypertension (13% vs. 4%); those that occurred 
less frequently included infusion reactions (1% vs. 16%) and any grade of IgM flare (8% vs. 47%). The 
major hemorrhage rate was the same in the two trial groups (4%). 
 
Interpretation  
Among patients with Waldenstrom’s macroglobulinemia, the use of ibrutinib– rituximab resulted in 
significantly higher rates of progression-free survival than the use of placebo–rituximab, both among 
those who had received no previous treatment and among those with disease recurrence. Atrial 
fibrillation and hypertension were more common with ibrutinib–rituximab, whereas infusion reactions 
and IgM flare were more common with placebo–rituximab. (Funded by Pharmacyclics and Janssen 
Research and Development; ClinicalTrials.gov number, NCT02165397.) 
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5 Breast Cancer 
5.1 Ribociclib (Kisqali®) plus endocrine therapy for premenopausal 
women with hormone-receptor-positive, advanced breast 
cancer 
Overview 
Drug Description 
 
a highly selective small-molecule inhibitor of CDK4 and 6 
 
Patient Indication premenopausal women with advanced, HR-positive breast cancer 
Incidence in 
Austria 
5,480 newly diagnosed per year (2015), 116.7/100,000 women/ year 
(European Standard Population, 2013) 
Ongoing Phase III - 
Approval 
status for 
this 
indication 
EMA - 
FDA 
according to label information (07/2018) ribociclib is indicated in 
combination with: 
- an aromatase inhibitor for the treatment of pre/perimenopausal or  
postmenopausal  women with hormone receptor (HR)-positive, 
human epidermal growth factor receptor 2 (HER2)-negative 
advanced or  metastatic breast cancer, as initial endocrine -based 
therapy 
Approval 
status for 
other 
indications 
EMA 
according to product information (07/2018) ribociclib  (in combination with 
an aromatase inhibitor) is indicated  for the treatment of postmenopausal  
women with hormone receptor (HR) –positive, human epidermal growth 
factor receptor 2 (HER2) -negative locally  advanced or metastatic breast 
cancer as initial endocrine -based therapy 
FDA 
according to label information (07/2018) ribociclib is indicated in 
combination with: 
- fulvestrant for the treatment of postmenopausal women with HR-
positive,  HER2 -negative advanced or metastatic breast cancer, 
as initial endocrine based therapy or following disease progression 
on endocrine therapy 
Costs  
21 Kisqali® 200 mg tablets = € 1,116.67 
42 Kisqali® 200 mg tablets = € 2,233.33 
63 Kisqali® 200 mg tablets = € 3,350.00 
 
Study patients received oral ribociclib (600 mg/day) on a 3-weeks-on, 
1-week-off schedule. Median duration of exposure to study treatment was 
15.2 months in patients of the ribociclib group. 
 
Based on study treatment, one month of ribociclib treatment costs € 
3,350.00. 
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Published articles (PubMed): 
Lancet Oncology; available May 24, 2018 (Tripathy et al.): “Ribociclib plus endocrine therapy for 
premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a 
randomised phase 3 trial” 
Background  
In MONALEESA-2, ribociclib plus letrozole showed improved progression-free survival compared with 
letrozole alone as first-line treatment for postmenopausal patients with hormone receptor (HR)-
positive, HER2-negative, advanced breast cancer. MONALEESA-7 aimed to assess the efficacy and 
safety of ribociclib plus endocrine therapy in premenopausal women with advanced, HR-positive 
breast cancer. 
 
Methods  
This phase 3, randomised, double-blind, placebo-controlled trial was done at 188 centres in 30 
countries. Eligible patients were premenopausal women aged 18–59 years who had histologically or 
cytologically confirmed HR-positive, HER2-negative, advanced breast cancer; an Eastern Cooperative 
Oncology Group performance status of 0 or 1; measurable disease as per Response Evaluation 
Criteria in Solid Tumors version 1.1 criteria, or at least one predominantly lytic bone lesion; and had 
not received previous treatment with cyclin-dependent kinases 4 and 6 inhibitors. Endocrine therapy 
and chemotherapy in the adjuvant or neoadjuvant setting was permitted, as was up to one line of 
chemotherapy for advanced disease. Patients were randomly assigned (1:1) via interactive response 
technology to receive oral ribociclib (600 mg/day on a 3-weeks-on, 1-week-off schedule) or matching 
placebo with either oral tamoxifen (20 mg daily) or a non-steroidal aromatase inhibitor (letrozole 2.5 
mg or anastrozole 1 mg, both oral, daily), all with goserelin (3.6 mg administered subcutaneously on 
day 1 of every 28-day cycle). Patients and investigators were masked to treatment assignment. 
Efficacy analyses were by intention to treat, and safety was assessed in all patients who received at 
least one dose of any study treatment. The primary endpoint was investigator-assessed progression-
free survival. MONALEESA-7 is registered with ClinicalTrials.gov, NCT02278120 and is ongoing, but 
no longer enrolling patients. 
 
Findings  
Between Dec 17, 2014, and Aug 1, 2016, 672 patients were randomly assigned: 335 to the ribociclib 
group and 337 to the placebo group. Per investigator’s assessment, median progression-free survival 
was 23.8 months (95% CI 19.2–not reached) in the ribociclib group compared with 13.0 months (11.0–
16.4) in the placebo group (hazard ratio 0.55, 95% CI 0.44–0.69; p<0.0001). Grade 3 or 4 adverse 
events reported in more than 10% of patients in either group were neutropenia (203 [61%] of 335 
patients in the ribociclib group and 12 [4%] of 337 in the placebo group) and leucopenia (48 [14%] and 
four [1%]). Serious adverse events occurred in 60 (18%) of 335 patients in the ribociclib group and 39 
(12%) of 337 in the placebo group, of which 15 (4%) and six (2%), respectively, were attributed to the 
study regimen. 12 (4%) of 335 patients in the ribociclib group and ten (3%) of 337 in the placebo group 
discontinued treatment because of adverse events. No treatment-related deaths occurred. 11 deaths 
occurred (five [1%] in the ribociclib group and six [2%] in the placebo group) during or within 30 days 
after treatment, most of which were due to progression of the underlying breast cancer (three [1%] and 
six [2%]). The remaining two deaths in the ribociclib group were due to an intracranial haemorrhage in 
an anticoagulated patient, and a pre-existing wound haemorrhage in another patient. 
 
Interpretation  
Ribociclib plus endocrine therapy improved progression-free survival compared with placebo plus 
endocrine therapy, and had a manageable safety profile in patients with premenopausal, HR-positive, 
HER2-negative, advanced breast cancer. The combination could represent a new first-line treatment 
option for these patients. 
